Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis.

IF 1.9 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2025-10-01 DOI:10.1080/1354750X.2025.2556170

Soumya Patil, Raushan Kumar Chaudhary, Prakash Patil, Praveenkumar Shetty, Vijith Vittal Shetty, Krishna Sharan, Uday Venkat Mateti

{"title":"Unveiling the oncogenic role and prognostic value of ACTL6A in cancer: a systematic review and meta-analysis.","authors":"Soumya Patil, Raushan Kumar Chaudhary, Prakash Patil, Praveenkumar Shetty, Vijith Vittal Shetty, Krishna Sharan, Uday Venkat Mateti","doi":"10.1080/1354750X.2025.2556170","DOIUrl":null,"url":null,"abstract":"Background: Actin-like protein 6 A (ACTL6A), a subunit of SWItch/sucrose non-fermentable (SWI/SNF) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumourigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance.Methods: A systematic search in PubMed, Scopus and Web of Science was conducted from inception to 31 December 2024, using the keywords 'ACTL6A' and 'Cancer'. Studies investigating ACTL6A's role in cancer and those reporting hazard ratios (HRs) for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively.Results: A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumuorigenesis, invasion and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumour size (p < 0.01) and higher tumour grade (p = 0.002).Conclusion: ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-13"},"PeriodicalIF":1.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2025.2556170","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Actin-like protein 6 A (ACTL6A), a subunit of SWItch/sucrose non-fermentable (SWI/SNF) complex has emerged as a key player in cancer progression. Despite growing evidence of its oncogenic potential, a comprehensive evaluation of its role in tumourigenesis and clinical outcomes remains warranted. This systematic review and meta-analysis aim to elucidate the role of ACTL6A in cancer pathophysiology and its prognostic significance.

Methods: A systematic search in PubMed, Scopus and Web of Science was conducted from inception to 31 December 2024, using the keywords 'ACTL6A' and 'Cancer'. Studies investigating ACTL6A's role in cancer and those reporting hazard ratios (HRs) for ACTL6A expression in human samples were considered for systematic review and meta-analysis, respectively.

Results: A total of 39 studies were included in systematic review which collectively reported the role of ACTL6A in tumuorigenesis, invasion and metastasis via HIPPO-YAP, PI3K/AKT, NOTCH and Wnt/β-catenin pathways. Six studies (n = 863) qualified for meta-analysis, revealing that ACTL6A overexpression was significantly associated with poor overall survival (OS) (p = 0.001), larger tumour size (p < 0.01) and higher tumour grade (p = 0.002).

Conclusion: ACTL6A is a critical oncogenic driver which promotes cancer progression and poor clinical outcomes. ACTL6A may serve as a promising prognostic marker, paving the way for targeted therapeutic strategies in oncology.

查看原文本刊更多论文

揭示ACTL6A在癌症中的致癌作用和预后价值：一项系统综述和荟萃分析。

背景：肌动蛋白样蛋白6A （ACTL6A）是SWI/SNF（开关/蔗糖不可发酵）复合物的一个亚基，在癌症进展中起着关键作用。尽管越来越多的证据表明其致癌潜力，但仍有必要对其在肿瘤发生和临床结果中的作用进行全面评估。本系统综述和荟萃分析旨在阐明ACTL6A在肿瘤病理生理中的作用及其预后意义。方法：以“ACTL6A”和“Cancer”为关键词，系统检索PubMed、Scopus和Web of Science，检索时间为成立之日至2024年12月31日。调查ACTL6A在癌症中的作用的研究和报告人类样本中ACTL6A表达的风险比分别被考虑进行系统评价和荟萃分析。结果：系统回顾共纳入39项研究，这些研究共同报道了ACTL6A通过hipo - yap、PI3K/AKT、NOTCH和Wnt/β-catenin通路在肿瘤发生、侵袭和转移中的作用。6项研究（n = 863）符合meta分析，结果显示ACTL6A过表达与较差的总生存期（OS）（p = 0.001）和较大的肿瘤大小（p = 0.002）显著相关。结论：ACTL6A是促进肿瘤进展和不良临床结果的关键致癌驱动因子。ACTL6A可能作为一个有希望的预后标志物，为肿瘤靶向治疗策略铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.